
    
      Latest amendment clarifies that Chronic Lymophocytic Leukemia (CLL) includes T-cell
      Prolymphocytic Leukemia (T-PLL). Prior treatment with some drugs targeting mTOR, P13K and
      related pathways is now permitted.
    
  